Germany - Drugs
For more information and to make a bid you will need to go to the third party website.
Details
Provided by
- Opportunity closing date
- 08 August 2025
- Opportunity publication date
- 22 August 2023
- Category
- 33600000
- Value of contract
- £0-100k
- Your guide to exporting
Description
§ Section 130a (8) SGB V enables health insurance funds (KK) and pharmaceutical companies to conclude framework discount agreements on drugs to be dispensed at the expense of the statutory KK. GWQ acts as a company for efficiency and quality at KK according to § 130a Abs. 8 S. 5 SGBV for its shareholder and customer health insurance companies. With regard to the relevant legal regulations for the award of public contracts, a regular process of active ingredient-related, formal award procedures in accordance with the regulations of the 4th part of the GWB is carried out by GWQ ServicePlus AG. Until the entry into force of new drug rebate contracts, GWQ would like to conclude drug rebate contracts with all interested pharmaceutical companies within the framework of the open house procedure for the active ingredient Epoetin alfa. Start of contract is 01.10.2023
GWQ ServicePlus AG intends to conclude non-exclusive rebate agreements in accordance with Section 130a (8) SGB V for the above-mentioned active ingredient. All interested companies can join this agreement at any time during the term of the agreement under the same conditions (approval model). GWQ assumes that this procedure does not fall within the scope of application of antitrust law due to the lack of a selection decision and therefore the non-discriminatory access of all pharmaceutical companies. In order to do justice to the diversity of the contractual partners within the framework of the approval model, each pharmaceutical company will be enabled to conclude a framework agreement at any time and under the same conditions during the term of the agreement. The contract documents, the participating health insurance companies, and the dates for notification of the contract can be viewed and downloaded from the GWQ ServicePlus AG contracting portal at http://vergabeportal.gwq-serviceplus.de. Upon receipt of the signed contracts on the 10th of each month, a notification can be realized for the next notification month.The following documents must be submitted:- signed contract in duplicate;- proof of the drug regulatory approval by means of an excerpt from the public part of the AMIce database;- signed self-declaration (Annex 3)- list of the PZNs subject to the contract (Annex 2) - declaration on Council Regulation (EU) 2022/576 of 08. April 2022 amending Regulation (EU) No 833/2014 concerning restrictive measures in view of Russia's actions destabilizing the situation in Ukraine (Annex 5).
- Opportunity closing date
- 08 August 2025
- Value of contract
- £0-100k
About the buyer
- Address
- GWQ ServicePlus AG GWQ ServicePlus AG, Ria-Thiele-Straße 2a, 40549 Düsseldorf, handelnd für die unter VI 3.) näher genannten Gesetzlichen Krankenkassen Düsseldorf 40549 Germany
- Contact
- bieteranfrage@gwq-serviceplus.de
Bid for tender
If your company meets the requirements of the tender, go to the website where the tender is hosted and submit your bid.
This website contains links to other websites that we do not control or maintain. We are not responsible for the content of these sites. We provide these links for your convenience only, and do not necessarily endorse their content.
Before entering into a contract you need to apply for any necessary export licences, which can include applications to trade in certain goods. You should also make your own enquiries and be satisfied by the accuracy of any information supplied to you.
This opportunity has been translated from its original language. You should check if you need to apply in the original language.